Hoth Therapeutics, Inc
Edit

Hoth Therapeutics, Inc

http://www.hoththerapeutics.com/
Last activity: 27.03.2024
Categories: DrugHealthTechITLifeMarketMedTechScienceSpace
Hoth Therapeutics, Inc. (NASDAQ: HOTH) is a biopharmaceutical visionary dedicated to finding, investigating and developing early-stage therapeutics that will change the way diseases are managed and treated. Guided by the belief that treatment should not make you sicker than the disease, Hoth Therapeutics seeks out overlooked drugs that hold the promise to improve treatments and address significant unmet needs for patients. Hoth Therapeutics follows the science to find the ideal indications for each asset and partners with leading companies in the space to bring therapies to market. At Hoth Therapeutics, we understand how devastating it can be to live with a chronic illness, be diagnosed with a rare disease, or the only option is to take a medicine that causes unrelenting side effects. We believe that every patient deserves to get the therapies they need to address their disease and improve their quality of life.
Followers
68
Followers
424
Mentions
98
Location: United States, New York
Employees: 1-10
Total raised: $3M
Founded date: 2017
Twitter
LinkedIn
Email

Investors 1

Funding Rounds 1

DateSeriesAmountInvestors
22.02.2018Series A$3M-

Mentions in press and media 98

DateTitleDescriptionSource
27.03.2024Hoth Therapeutics Announces Exercise of Warrants for $4.2 Mi...NEW YORK, March 27, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused b...salamancap...
30.12.2022Hoth Therapeutics Announces $10 Million Private Placement Pr...NEW YORK, Dec. 29, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. HOTH, a patient-focused biopharmaceu...einpresswi...
09.02.2022Hoth Therapeutics Announces the selection of NUVISAN for Man...NEW YORK, Feb. 9, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused bio...marketscre...
07.02.2022Hoth Therapeutics Announces Presentation of the HT-ALZ Proof...NEW YORK, Feb. 7, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused bio...marketscre...
31.01.2022Hoth Therapeutics Announces the Appointment of John Cirrito,...NEW YORK, Jan. 31, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused bi...marketscre...
04.01.2022Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Positiv...NEW YORK, Jan. 4, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused bio...marketscre...
04.01.2022Hoth Therapeutics : Announces HT-ALZ Therapeutic Shows Posit...Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Positive Results - Reduce Amyloid β in Alzheime...marketscre...
21.12.2021Hoth Therapeutics Announces Submission of Orphan Drug Design...NEW YORK, Dec. 21, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a patient-focused cli...marketscre...
08.12.2021Systemic Lupus Erythematosus Treatment Market Projected To R...PALM BEACH, Fla., Dec. 8, 2021 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - Systemic Lup...salamancap...
08.12.2021Hoth Therapeutics Licenses Lupus Therapeutic Back to Zylö Th...NEW YORK, Dec. 8, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biop...marketscre...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In